Biological agents and tuberculosis: Risk estimates and screening strategies

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

[Extract] The introduction of biological agents has revolutionized the management of rheumatic diseases. However, the immunomodulatory effect of these drugs is associated with an increased risk of infection, especially an increased risk of tuberculosis (TB) reactivation – a fact of which the medical community has been well aware ever since a study on TB case reports after infliximab therapy was published in 2001. The recognition of an increased risk of TB reactivation in patients on tumor necrosis factor‐alpha (TNF‐α) inhibitor treatment has led to the publication of numerous guidelines on screening and treatment for latent TB infection (LTBI) in these patients, but many uncertainties remain.
Original languageEnglish
Pages (from-to)264-267
Number of pages4
JournalInternational Journal of Rheumatic Diseases
Volume18
Issue number3
DOIs
Publication statusPublished - 1 Jan 2015
Externally publishedYes

Fingerprint

Biological Factors
Tuberculosis
Latent Tuberculosis
Rheumatic Diseases
Uncertainty
Publications
Necrosis
Therapeutics
Guidelines
Infection
Pharmaceutical Preparations
Neoplasms

Cite this

@article{a917672cba0a4b1199bc4a0f246a4665,
title = "Biological agents and tuberculosis: Risk estimates and screening strategies",
abstract = "[Extract] The introduction of biological agents has revolutionized the management of rheumatic diseases. However, the immunomodulatory effect of these drugs is associated with an increased risk of infection, especially an increased risk of tuberculosis (TB) reactivation – a fact of which the medical community has been well aware ever since a study on TB case reports after infliximab therapy was published in 2001. The recognition of an increased risk of TB reactivation in patients on tumor necrosis factor‐alpha (TNF‐α) inhibitor treatment has led to the publication of numerous guidelines on screening and treatment for latent TB infection (LTBI) in these patients, but many uncertainties remain.",
author = "Dobler, {Claudia C.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/1756-185X.12672",
language = "English",
volume = "18",
pages = "264--267",
journal = "APLAR Journal of Rheumatology",
issn = "1756-1841",
publisher = "Wiley-Blackwell",
number = "3",

}

Biological agents and tuberculosis : Risk estimates and screening strategies. / Dobler, Claudia C.

In: International Journal of Rheumatic Diseases, Vol. 18, No. 3, 01.01.2015, p. 264-267.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Biological agents and tuberculosis

T2 - Risk estimates and screening strategies

AU - Dobler, Claudia C.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - [Extract] The introduction of biological agents has revolutionized the management of rheumatic diseases. However, the immunomodulatory effect of these drugs is associated with an increased risk of infection, especially an increased risk of tuberculosis (TB) reactivation – a fact of which the medical community has been well aware ever since a study on TB case reports after infliximab therapy was published in 2001. The recognition of an increased risk of TB reactivation in patients on tumor necrosis factor‐alpha (TNF‐α) inhibitor treatment has led to the publication of numerous guidelines on screening and treatment for latent TB infection (LTBI) in these patients, but many uncertainties remain.

AB - [Extract] The introduction of biological agents has revolutionized the management of rheumatic diseases. However, the immunomodulatory effect of these drugs is associated with an increased risk of infection, especially an increased risk of tuberculosis (TB) reactivation – a fact of which the medical community has been well aware ever since a study on TB case reports after infliximab therapy was published in 2001. The recognition of an increased risk of TB reactivation in patients on tumor necrosis factor‐alpha (TNF‐α) inhibitor treatment has led to the publication of numerous guidelines on screening and treatment for latent TB infection (LTBI) in these patients, but many uncertainties remain.

UR - http://www.scopus.com/inward/record.url?scp=84928543341&partnerID=8YFLogxK

U2 - 10.1111/1756-185X.12672

DO - 10.1111/1756-185X.12672

M3 - Article

VL - 18

SP - 264

EP - 267

JO - APLAR Journal of Rheumatology

JF - APLAR Journal of Rheumatology

SN - 1756-1841

IS - 3

ER -